BetterLife Pharma Provides Scientific Update on Neuroplastogenic Activity of BETR-001

Core Insights - BetterLife Pharma Inc. is focused on developing BETR-001, a non-hallucinogenic neuroplastogen aimed at treating psychiatric and neurological disorders [1][8] - BETR-001 has shown significant potential in promoting neuroplasticity, which is crucial for brain rewiring and forming new neuronal connections [2][4] - The company has received a composition of matter patent for BETR-001 and is preparing for IND filing and human trials projected for H1 2026 [7][9] Group 1: Scientific Developments - BETR-001 has been demonstrated to significantly induce the formation of new dendrites and spines in cultured rat brain cortical neurons, outperforming ketamine in these aspects [2][3] - The drug's neuroplasticity data suggests its effectiveness in treating various conditions such as depression, anxiety, PTSD, traumatic brain injury, migraines, and neuropathic pain [4][9] Group 2: Regulatory and Development Status - BetterLife has completed most of the required IND-enabling studies and has had a pre-IND meeting with the FDA [7] - The company is also developing BETR-002, which targets anxiety-related disorders, and is exploring strategic alternatives for other drug candidates [10]